Xtampza Er was Collegium Pharmaceutical’s largest product and service line in fiscal 2025, bringing in $199.31M of $329.07M (61%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Xtampza Er | $138.80M | $177.37M | $191.33M | $199.31M | |||||
| Belbuca | $126.46M | $182.10M | $211.27M | — | |||||
| Nucynta Ir | $112.06M | $108.15M | $100.74M | $115.31M | |||||
| Nucynta Er | $72.42M | $82.65M | $75.77M | — | |||||
| Jornay Pm | — | — | $37.24M | — | |||||
| Symproic & Other | — | $16.50M | $15.10M | $14.45M | |||||
| Symproic | $12.27M | — | — | — | |||||
| Other | $1.93M | — | — | — | |||||
| Total | $463.93M | $566.77M | $631.45M | $329.07M |
Collegium Pharmaceutical brought in $329.07M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. Collegium Pharmaceutical regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $631.45M. Xtampza Er was the largest at $199.31M (60.6%), ahead of Nucynta Ir at $115.31M (35.0%) and Symproic & Other at $14.45M (4.4%).
Compared with fiscal 2024, Nucynta Ir grew fastest, up 14.5% to $115.31M, while Symproic & Other fell the most, down 4.3% to $14.45M.
Collegium Pharmaceutical began breaking out Symproic & Other in fiscal 2023, when it brought in $16.50M. Collegium Pharmaceutical stopped reporting Belbuca ($211.27M in fiscal 2024), Nucynta Er ($75.77M in fiscal 2024), Jornay Pm ($37.24M in fiscal 2024) and two others as separate lines.
Collegium Pharmaceutical (COLL) reports its revenue by product and service. In fiscal 2025, Xtampza Er was its largest product and service line, bringing in $199.31M (60.6% of the total), followed by Nucynta Ir at $115.31M (35.0%).
Xtampza Er was Collegium Pharmaceutical's largest product and service line in fiscal 2025, bringing in $199.31M, or 60.6% of the $329.07M total across its three product and service lines.
Every figure comes from Collegium Pharmaceutical's annual financial filings, as reported. Each line keeps the name Collegium Pharmaceutical gives it, and years follow its fiscal calendar.
Collegium Pharmaceutical's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.